

ioOligodendrocyte-like cells™

Human iPSC-derived oligodendrocyte-like cells Learn more about ioOligodendrocyte-like cells





About the cells

ioOligodendrocyte-like cells resemble a premyelinating oligodendrocyte state. These highly characterised cells enable the screening of compounds that modulate myelination, supporting drug development for neurodegenerative and demyelinating diseases, such as multiple sclerosis.

ioOligodendrocyte-like cells are precision reprogrammed from human iPSCs using opti-ox[™] technology, meaning scalability and consistency are built-in.

Benchtop benefits



DEFINED

Induction Production of ioOligodendrocyte-like

cells

Day 1

Human O4+ cells initially display a typical OPC-like morphology. They mature into oligodendrocyte-like cells that have multiple branched processes.

Customer

- Revival of cells

1

Cells arrive ready to plate

Cells show an oligodendrocytelike morphology by day 8

QUICK

Delivery of cells in a cryopreserved format.

Culture of ioOligodendrocyte-like cells in

customer's laboratory in recommended media.

2

3

4

Time (days)

5



1 post-revival and rapidly mature into O4+ MBP+ oligodendrocyte-like cells with an 8 day protocol.

EASY TO USE

Cryopreserved cells arrive ready to be used upon revival. Simple monolayer culture protocol. No lentiviral transduction required.

7

ioOligodendrocytelike cells rapidly express oligodendroglialspecific markers

Key oligodendroglial genes are expressed by the cells

Protein expression

Immunofluorescent staining of the cells at day 1 (upper panel) and day 8 (lower panel) post-revival. At day 1, the cells are positive for the oligodendrocyte-specific marker O4 (red), and the DAPI counterstain (blue). At day 8, ioOligodendrocytelike cells show an increased complexity and are positive for O4 (red), the myelin basic protein (MBP) (green), and the DAPI counterstain (blue). 100X magnification; scale bar: 100 µm.

Gene expression

Following reprogramming, the cells downregulate expression of the pluripotency gene OCT4, whilst demonstrating robust expression of relevant oligodendroglial markers, including PDGFRA, PLP1, MBP, CNP, MAG, and MYRF. Gene expression levels assessed by RT-qPCR, data expressed relative to the reference (housekeeping) gene, HMBS. Data represents day 1 and day 8 post-revival samples; n=2 technical replicates.

Whole transcriptome analysis demonstrates high lot-to-lot consistency

Bulk RNA-sequencing analysis was performed on three manufactured lots of ioOligodendrocyte-like cells at day 1 and day 8 post-revival

Principal component analysis (PCA) represents the variance in gene expression between the three different lots of ioOligodendrocytelike cells. This analysis shows lots clustering very closely which demonstrates high consistency at each given timepoint. This lotto-lot consistency in every vial gives scientists confidence in their experimental reproducibility. Colours represent the parental non-induced hiPSC cell line and the three lots of ioOligodendrocytelike cells; shapes represent different timepoints.

Upon reprogramming, cells show rapid morphological changes, acquiring an OPC-like morphology by day 1 post-revival.

0

By day 8, cells have matured and display an oligodendrocyte-like morphology. Brightfield images show day 1 and day 8 post-thawing; scale bar: 400 µm.

6



0 µm 400 1.75 x 1.29 mm, 2.27 mm²







- Lot3

Product information

Cat code ioC028

Starting material Human iPSC line

Karyotype 46, XY*

*High-resolution Optical Genome Mapping (OGM) has identified a ~16mb gain of the short arm of chromosome 12

Seeding compatibility 6, 12, 24 well plates

Shipping info Dry ice

Donor Caucasian adult male (skin fibroblast)

Vial size Small: >1 x 10⁶ viable cells

Quality control Sterility, protein expression (ICC) and gene expression (RT-qPCR)

Differentiation method opti-ox[™] cell reprogramming

Recommended seeding density 27,000 cells/cm²

User storage LN2

Format Cryopreserved cells

Product use ioCells[™] are for research use only

Applications Screening of compounds that modulate myelination, phenotypic assays, target validation

Who we are

bit.bio combines the concepts of cell programming and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.

This is possible with our precision human cellular reprogramming technology opti-ox[™] – a gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale

For general information, email info@bit.bio

To learn more, visit www.bit.bio

